Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MagIA Diagnostics has developed a patented point-of-care diagnostic device capable of detecting up to ten immunological markers in blood within 12 minutes. The technology has completed prototyping, industrialization, clinical validation phases in France (Marseille and Perpignan), and entered the final regulatory submission phase as of mid-2025. A large-scale prospective study involving 7,500 pregnant women in the DRC will assess real-world impact on access to care. The company aims for CE marking/commercial launch by 2026.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MagIA Diagnostics.